Clinical Trial Update: Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial is evaluating a gene therapy drug for Spinal Muscular Atrophy Type 3. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy Type

Drugs mentioned

• Gene therapy drug

Snippet

Sponsor: GeneCradle Inc | Conditions: Spinal Muscular Atrophy Type 3 | Phase 1, Phase 2 | Status: RECRUITING